Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

Share Price is delayed by 15 minutes
Get Live Data
8.00    -0.40 (-4.76%)
Bid:
7.50
Ask:
8.50
Spread: 1.00 (13.333%)
Market Cap: £506.60m
AGY Live PriceLast checked at - London Stock Exchange

Intraday Allergy Thera. Share Chart

Form 8 (DD)

5 Sep 2023 11:24

RNS Number : 4477L
finnCap
05 September 2023
 

These transactions have taken place as a consequence of book flattening. The Panel Executive has informed finnCap Ltd on an ex parte basis that such transactions are permitted and have no Code consequences.

 

FORM 8 (DD)

 

PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS)

Rules 8.1, 8.2 and 8.4 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

finnCap Ltd

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Allergy Therapeutics Plc (AGY)

(d) Status of person making the disclosure:

e.g. offeror, offeree, person acting in concert with the offeror/offeree (specify name of offeror/offeree)

Advisor to offeror Skygem Acquisition Limited (an indirect wholly-owned subsidiary of funds managed by ZQ Capital Management Limited)

(e) Date dealing undertaken:

04/09/2023

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

NO

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing

 

Class of relevant security:

 

Ordinary 0.1p

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

Nil

 

Nil

 

(2) Cash-settled derivatives:

 

Nil

 

Nil

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

Nil

 

Nil

 

 

TOTAL:

Nil

 

Nil

 

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

 

Details, including nature of the rights concerned and relevant percentages:

 

 

3. DEALINGS BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

(i) Party to an offer or person acting in concert (except for a principal trader in the same group as a connected adviser)

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

Ordinary GBP 0.001

SELL

 

1

2.76 pence

 

(ii) Principal trader where the sole reason for the connection is that the principal trader is in the same group as a connected adviser

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

 

 

 

 

 

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer or person acting in concert making the disclosure and any other person:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer or person acting in concert making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

 

 

Date of disclosure:

05/09/2023

Contact name:

Mark Tubby

Telephone number:

02072200504

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DCCEAENSEAADEFA
Date   Source Headline
4th Oct 20123:57 pmRNSHolding(s) in Company
17th Sep 20127:00 amRNSFinal Results
30th Aug 201211:14 amRNSNotice of results and shareholder update
3rd Aug 20127:00 amRNSFDA Clinical Hold Lifted
31st May 20122:34 pmRNSHolding(s) in Company
23rd May 201211:23 amRNSVoluntary recall of Anapen by Lincoln Medical
17th May 20124:51 pmRNSHolding(s) in Company
17th May 20124:51 pmRNSHolding(s) in Company
16th May 201211:11 amRNSTotal Voting Rights
2nd May 20123:33 pmRNSBoard Appointment
24th Apr 201212:31 pmRNSHolding(s) in Company
20th Apr 20128:01 amRNSConcert Party Shareholding
20th Apr 20128:01 amRNSDirector/PDMR Shareholding
19th Apr 20123:05 pmRNSResult of AGM
18th Apr 20127:00 amRNSResult of Offer
30th Mar 20127:02 amRNSGrant of Options
30th Mar 20127:01 amRNSFundraising Announcement
30th Mar 20127:00 amRNSHalf Yearly Report
14th Mar 20129:23 amRNSNotice of results and shareholder update
21st Feb 20126:12 pmRNSHolding(s) in Company
21st Feb 20126:11 pmRNSHolding(s) in Company
6th Dec 20117:00 amRNSAnapen® 500mcg epinephrine auto-injector
28th Nov 20117:00 amRNSRegulatory update PEI FDA
16th Nov 20115:20 pmRNSAGM Statement
20th Oct 20116:24 pmRNSAnnual Financial Report
29th Sep 201112:45 pmRNSProvisional Grant of Options
19th Sep 20117:00 amRNSFinal Results
19th Sep 20117:00 amRNSDistribution Agreement
8th Sep 20115:06 pmRNSHolding(s) in Company
7th Sep 20117:00 amRNSNotice of Results
23rd Aug 20119:35 amRNSForm 8.3 - [Allergy Therapeutics]
23rd Aug 20117:00 amRNSAllergy Therapeutics enters Latin America
22nd Aug 201112:03 pmRNSForm 8.3 - [Allergy Therapeutics Plc]
8th Jun 20117:00 amRNSRegulatory Update
28th Apr 20117:00 amRNSTotal Voting Rights
26th Apr 20117:00 amRNSFDA Update
20th Apr 20112:59 pmRNSExercise of Options
11th Apr 20114:31 pmRNSHolding(s) in Company
7th Apr 20117:00 amRNSGrass MATA MPL dossier submitted in Switzerland
30th Mar 20116:19 pmRNSDirector/PDMR Shareholding
29th Mar 20113:19 pmRNSDirector/PDMR Shareholding
29th Mar 20113:17 pmRNSDirector/PDMR Shareholding
28th Mar 20117:02 amRNSU.S. regulatory update
28th Mar 20117:00 amRNSHalf Yearly Report
9th Feb 201110:32 amRNSHolding(s) in Company
9th Feb 201110:31 amRNSHolding(s) in Company
1st Dec 20107:00 amRNSTen further MAAs submitted in Germany
18th Nov 201011:52 amRNSResult of AGM
20th Oct 20108:06 amRNSAnnual Financial Report
4th Oct 20109:45 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.